Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 5 (2008), Issue 3 (March)

1. Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer.
   Cancer, 112(5): 1169-77. [Abstract] [Full-text]
2. Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis.
   Int J Cancer, 122(9): 1923-30. [Abstract] [Full-text]
3. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma.
   Int J Cancer, 122(9): 2125-9. [Abstract] [Full-text]
4. Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo.
   Gene Ther, 15(6): 424-33. [Abstract] [Full-text]
5. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.
   J Natl Cancer Inst, 100(5): 359-72. [Abstract] [Full-text]
6. Ovarian undifferentiated carcinoma resembling giant cell carcinoma of the lung.
   Pathol Int, 58(4): 244-8. [Abstract] [Full-text]
7. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
   J Clin Oncol, 26(8): 1331-7. [Abstract] [Full-text]
8. Lymphovascular space invasion does not predict vaginal relapses in stage I endometrioid adenocarcinoma of the endometrium.
   Ann Diagn Pathol, 12(2): 112-7. [Abstract] [Full-text]
9. Differences in characteristics among 1,000 women with endometriosis based on extent of disease.
   Fertil Steril, 89(3): 538-45. [Abstract] [Full-text]
10. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.
    Ann Surg Oncol, 15(4): 1183-92. [Abstract] [Full-text]
11. Cystic struma ovarii presenting as pseudo-Meigs' syndrome with elevated CA125 levels. A case report and review of the literature.
    Int J Gynecol Cancer, 18(2): 372-5. [Abstract] [Full-text]
12. Role of diaphragmatic surgery in 69 patients with ovarian carcinoma.
    Int J Gynecol Cancer, 18(2): 363-8. [Abstract] [Full-text]
13. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology.
    Int J Gynecol Cancer, 18(2): 269-73. [Abstract] [Full-text]
14. A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum.
    Int J Gynecol Cancer, 18(2): 249-54. [Abstract] [Full-text]
15. P53 and bcl-2 assessment in serous ovarian carcinoma.
    Int J Gynecol Cancer, 18(2): 241-8. [Abstract] [Full-text]
16. Mucinous ovarian cancer.
    Int J Gynecol Cancer, 18(2): 209-14. [Abstract] [Full-text]
17. Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary.
    Int J Gynecol Cancer, 18(2): 379-83. [Abstract] [Full-text]
18. Prognostic impact of body mass index and effect of overweight and obesity on surgical and adjuvant treatment in early-stage epithelial ovarian cancer.
    Int J Gynecol Cancer, 18(2): 345-51. [Abstract] [Full-text]
19. The role of frozen section evaluation in the diagnosis of adnexal mass.
    Int J Gynecol Cancer, 18(2): 235-40. [Abstract] [Full-text]
20. Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2 in patients with recurrent ovarian and peritoneal cancer.
    Int J Gynecol Cancer, 18(2): 223-7. [Abstract] [Full-text]
21. Weekly cisplatin with oral etoposide: a well-tolerated and highly effective regimen in relapsed ovarian cancer.
    Int J Gynecol Cancer, 18(2): 228-34. [Abstract] [Full-text]
22. The alarm anti-protease, secretory leukocyte protease inhibitor, is a proliferation and survival factor for ovarian cancer cells.
    Carcinogenesis, 29(3): 466-72. [Abstract] [Full-text]
23. Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy.
    Jpn J Clin Oncol, 38(3): 214-21. [Abstract] [Full-text]
24. Anaplastic carcinoma in mucinous ovarian tumors: a clinicopathologic study of 34 cases emphasizing the crucial impact of stage on prognosis, their histologic spectrum, and overlap with sarcomalike mural nodules.
    Am J Surg Pathol, 32(3): 383-9. [Abstract] [Full-text]
25. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.
    Clin Genet, 73(4): 338-45. [Abstract] [Full-text]
26. Protein tyrosine phosphatase inhibition induces anti-tumor activity: evidence of Cdk2/p27 kip1 and Cdk2/SHP-1 complex formation in human ovarian cancer cells.
    Cancer Lett, 262(2): 265-75. [Abstract] [Full-text]
27. Simultaneous development and parallel course of disseminated superficial porokeratosis and ovarian cancer: Coincidental association or true paraneoplastic syndrome?
    J Am Acad Dermatol, 58(4): 657-60. [Abstract] [Full-text]
28. Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus.
    Am J Clin Pathol, 129(4): 592-605. [Abstract] [Full-text]
29. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study.
    J Natl Cancer Inst, 100(6): 399-406. [Abstract] [Full-text]
30. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.
    Diagn Mol Pathol, 17(1): 34-8. [Abstract] [Full-text]
31. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.
    Int J Gynecol Pathol, 27(2): 151-60. [Abstract] [Full-text]
32. Histologic subtypes of ovarian carcinoma: an overview.
    Int J Gynecol Pathol, 27(2): 161-74. [Abstract] [Full-text]
33. Grading of ovarian cancer: a histotype-specific approach.
    Int J Gynecol Pathol, 27(2): 175-81. [Abstract] [Full-text]
34. Women with undiagnosed colorectal adenocarcinomas presenting with ovarian metastases: clinicopathologic features and comparison with women having known colorectal adenocarcinomas and ovarian involvement.
    Int J Gynecol Pathol, 27(2): 182-90. [Abstract] [Full-text]
35. The prognostic and predictive value of syntactic structure analysis in serous carcinoma of the ovary.
    Int J Gynecol Pathol, 27(2): 191-8. [Abstract] [Full-text]
36. Immunohistochemical analysis of reserve cell-like cells of ovarian müllerian mucinous/mixed epithelial borderline tumor.
    Int J Gynecol Pathol, 27(2): 199-206. [Abstract] [Full-text]
37. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
    Int J Gynecol Pathol, 27(2): 207-12. [Abstract] [Full-text]
38. Highly differentiated follicular carcinoma arising from struma ovarii: a report of 3 cases, a review of the literature, and a reassessment of so-called peritoneal strumosis.
    Int J Gynecol Pathol, 27(2): 213-22. [Abstract] [Full-text]
39. Krukenberg tumor with yolk sac tumor differentiation.
    Int J Gynecol Pathol, 27(2): 223-8. [Abstract] [Full-text]
40. Uterine tumors resembling ovarian sex cord tumors: an update.
    Int J Gynecol Pathol, 27(2): 229-35. [Abstract] [Full-text]
41. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Cancer, 112(7): 1489-502. [Abstract] [Full-text]
42. Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion.
    Cancer, 112(7): 1632-41. [Abstract] [Full-text]
43. Estrogen-dependent cell signaling and apoptosis in BRCA1-blocked BG1 ovarian cancer cells in response to plumbagin and other chemotherapeutic agents.
    Ann Oncol, 19(4): 696-705. [Abstract] [Full-text]
44. Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review.
    Ann Oncol, 19(4): 688-95. [Abstract] [Full-text]
45. Risk factors for ovarian cancer: an overview with emphasis on hormonal factors.
    J Toxicol Environ Health B Crit Rev, 11(3): 301-21. [Abstract] [Full-text]
46. Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.
    J Mol Endocrinol, 40(4): 161-72. [Abstract] [Full-text]
47. Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma.
    Gynecol Oncol, 109(1): 122-8. [Abstract] [Full-text]
48. Selenium-Binding Protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer.
    Gynecol Oncol, 109(1): 115-21. [Abstract] [Full-text]
49. Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.
    Gynecol Oncol, 109(1): 27-32. [Abstract] [Full-text]
50. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
    Gynecol Oncol, 109(1): 33-8. [Abstract] [Full-text]
51. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
    Gynecol Oncol, 109(1): 97-106. [Abstract] [Full-text]
52. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment.
    Gynecol Oncol, 109(1): 129-39. [Abstract] [Full-text]
53. Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer.
    Gynecol Oncol, 109(1): 39-42. [Abstract] [Full-text]
54. Beta-hydroxyisovalerylshikonin has a profound anti-growth activity in human endometrial and ovarian cancer cells.
    Gynecol Oncol, 109(1): 107-14. [Abstract] [Full-text]
55. Occurrence of synchronous invasive lobular breast carcinoma and poorly differentiated ovarian carcinoma in a single peritoneal deposit.
    Oncology, 73(1): 136-40. [Abstract] [Full-text]
56. Angiogenesis as a strategic target for ovarian cancer therapy.
    Nat Clin Pract Oncol, 5(4): 194-204. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.